Basilea Takes On Partner J&J In Arbitration Claim Over Ceftobiprole Delays
Executive Summary
In an era where most product- and innovation-hungry big pharma firms have been desperately promoting themselves as "best partners," it is perhaps easy to forget what can go wrong when a biotech entrusts its asset to a larger firm
You may also be interested in...
Lesson From A Deal Gone Bad: Basilea Ups Role In New Astellas Partnership
Even before Switzerland's Basilea started arbitration proceedings a year ago against its now former partner Johnson & Johnson on antibiotic ceftobiprole, the biotech would have been drawing lessons on what to avoid - and what to insist upon -in future license agreements
Lesson From A Deal Gone Bad: Basilea Ups Role In New Astellas Partnership
Even before Switzerland's Basilea started arbitration proceedings a year ago against its now former partner Johnson & Johnson on antibiotic ceftobiprole, the biotech would have been drawing lessons on what to avoid - and what to insist upon -in future license agreements
J&J and Basilea End Ceftobiprole Deal
The news is, on the whole, good for Basilea, but questions remain on how the separation will actually work.